Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant dabrafenib + trametinib to enable complete resection in BRAF-mutant unresectable stage III/IV melanoma
NL-OMON38944Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in melanoma, sponsored by Netherlands Cancer Institute. Primary endpoint: R0 resection rate. Started Aug 2014; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON38944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38944.